742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination wi...
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
About this item
Full title
Author / Creator
Park, Jong Chul , Berz, David , Sharma, Manish , Massarelli, Erminia , Hauke, Ralph J , Tsai, Frank Yung-Chin , Hong, David , Akhave, Neal , Call, Justin A , Carlisle, Jennifer , Sanborn, Rachel E , Haas, Naomi B , Hamm, John , Ross Camidge, D , Spira, Alexander I , Andrianov, Vasily , O’Neill, Brianne , Kinkead, Heather and Tolcher, Anthony W
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Background4–1BB is a costimulatory receptor upregulated on tumor-infiltrating lymphocytes. 4–1BB signaling promotes T-cell proliferation and activation and decreases T-cell exhaustion. 4–1BB agonists have shown promising antitumor activity but have been limited by hepatotoxicity resulting from systemic 4–1BB activation.INBRX-105 is a 4–1BB×PD-L1 bi...
Alternative Titles
Full title
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
Authors, Artists and Contributors
Author / Creator
Berz, David
Sharma, Manish
Massarelli, Erminia
Hauke, Ralph J
Tsai, Frank Yung-Chin
Hong, David
Akhave, Neal
Call, Justin A
Carlisle, Jennifer
Sanborn, Rachel E
Haas, Naomi B
Hamm, John
Ross Camidge, D
Spira, Alexander I
Andrianov, Vasily
O’Neill, Brianne
Kinkead, Heather
Tolcher, Anthony W
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2dee67d863844cdca9915a4f49a31119
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2dee67d863844cdca9915a4f49a31119
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.0742
